Anxiety is not a personality trait. It is a neurochemical state. Specifically, it is the state that occurs when the brain's primary inhibitory neurotransmitter, gamma-aminobutyric acid (GABA), is not doing its job. Understanding GABA is critical for anyone dealing with addiction, because the anxiety-addiction loop is one of the most reliable predictors of relapse. People do not relapse because they want to get high. They relapse because they cannot tolerate the anxiety, and the anxiety has a physiological cause.
What GABA Does
If neurotransmitters were a stereo system, glutamate would be the volume knob and GABA would be the mute button. Glutamate is the brain's primary excitatory neurotransmitter, it makes neurons fire. GABA is the primary inhibitory neurotransmitter, it prevents neurons from firing. The balance between these two determines the overall excitatory tone of the nervous system.
When GABA is functioning normally, it acts as a brake on neural activity. It keeps the system from becoming overexcited. It is the reason you can sit quietly in a room without your thoughts spiraling. It is the reason your muscles relax when you lie down. It is the reason minor stressors do not trigger a full fight-or-flight cascade.
When GABA is depleted or its receptors are downregulated, those brakes fail. Neural circuits fire without adequate inhibition. The subjective experience is anxiety, racing thoughts, muscle tension, a sense of impending danger with no identifiable source, difficulty sleeping, and an overwhelming desire to find something, anything, that will make it stop.
How Substances Exploit the GABA System
Alcohol is the most direct GABA manipulator. It binds to GABA-A receptors and enhances their inhibitory effect. This is why alcohol feels calming. It is literally amplifying the brain's own braking system. Benzodiazepines, Valium, Xanax, Ativan, work through an almost identical mechanism. Both produce rapid, reliable anxiety relief by boosting GABAergic transmission.
The problem, as with every neurotransmitter system substances target, is adaptation. Chronic alcohol or benzodiazepine exposure causes the brain to downregulate GABA receptors and, simultaneously, upregulate glutamate receptors. The brain is trying to maintain equilibrium against a substance that keeps pushing the system toward sedation. It compensates by reducing its own inhibitory capacity and increasing its excitatory capacity.
This adaptation is the setup for a dangerous withdrawal. Remove the substance, and you have a brain with reduced GABA function and enhanced glutamate function. The brakes are weak and the accelerator is stuck. The clinical result is anxiety far worse than whatever the person was self-medicating in the first place. In severe cases, particularly with alcohol and benzodiazepines, this excitatory rebound can produce seizures, the most extreme expression of uninhibited neural firing.
Nicotine also affects GABA circuits, though less directly. Nicotine modulates GABA release in the ventral tegmental area, influencing the reward pathway and contributing to the anxiolytic effect that smokers describe. Cannabis acts on GABAergic interneurons in ways that are still being fully mapped but clearly contribute to the calming effects users report.
The Anxiety-Addiction Feedback Loop
This is where GABA depletion becomes especially insidious. The sequence runs like this:
A person experiences anxiety. They discover that a substance relieves it. They use the substance repeatedly. The brain downregulates GABA in response. When the substance wears off, anxiety returns, now worse than the original baseline because GABA function has been compromised. The person uses more of the substance to manage the increased anxiety. Further downregulation occurs. The cycle accelerates.
At some point, the person is no longer using the substance for its original purpose. They are using it to manage the withdrawal-induced anxiety that the substance itself created. They are running on a treadmill that is accelerating beneath them.
This loop explains why anxiety disorders and substance use disorders co-occur at rates far above chance. The National Institute on Drug Abuse estimates that individuals with anxiety disorders are roughly twice as likely to develop a substance use disorder. The relationship is bidirectional, anxiety drives use, and use deepens anxiety, creating a feedback loop that purely behavioral interventions struggle to break because the underlying GABA deficit persists regardless of the patient's cognitive insight.
GABA Recovery
GABA receptor recovery follows a different timeline than dopamine or endorphin recovery, and the trajectory depends heavily on the substance involved. Alcohol-related GABA changes can begin normalizing within weeks of abstinence for moderate users, but heavy, long-term drinkers may experience protracted anxiety for six months to a year. Benzodiazepine recovery is notoriously slow, some patients report persistent anxiety and sensory sensitivity for twelve to eighteen months after cessation.
During this recovery window, the person is neurologically primed for relapse. Every anxious episode is a direct experience of their impaired GABA system, and they know exactly what substance will provide immediate relief. The fact that the relief is temporary and self-defeating does not change the intensity of the urge, because the urge is not generated by rational circuitry. It is generated by a survival system that has learned to associate the substance with safety.
Supporting GABA Recovery Without Substances
The therapeutic challenge is providing GABA support during the recovery window without introducing another GABAergic substance that will perpetuate the same cycle. This is why replacing alcohol with benzodiazepines, while sometimes medically necessary for acute withdrawal safety, is not a long-term solution, it simply transfers the dependency to a different molecule acting on the same receptor system.
Non-pharmacological GABA support is where interventions like low-level laser therapy become relevant. Photobiomodulation has been shown to influence neurotransmitter balance through enhanced mitochondrial function and ATP production, creating conditions that support the brain's own GABA synthesis rather than artificially activating receptors from outside.
The anxiety treatment protocol at LaserQuit targets auricular and body points associated with GABAergic pathways. The aim is not to replicate the sedative effect of a substance but to reduce the severity of the GABA deficit during the recovery period, to take the edge off the rebound anxiety enough for the person to sleep, function, and remain abstinent while their receptors normalize.
Understanding GABA reframes anxiety during recovery from a psychological failing to a neurochemical event with a known mechanism and a known recovery timeline. That reframing matters. A person who believes their anxiety is evidence of personal weakness will self-medicate. A person who understands it as a temporary receptor deficit with a physiological solution is far more likely to endure it.